Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $8 price target on Rigel Pharmaceuticals after the company provided on update on Q4 Tavalisse performance which continues to see a "nice" upward launch trajectory, as well as continued increases in patient persistence, indicating "strong" uptake in the immune thrombocytopenic purpura setting. Raymond added that Rigel's announcement of Tavalisse's approval in Europe with the continued pipeline progress, he continues to like the setup on Rigel's shares and still sees the stock as one of the most under-appreciated commercial stories in the sector.